http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Novavax Expands Large-Scale Global Manufacturing Capacity
-
Novavax Expands Large-Scale Global Manufacturing Capacity
-
Novavax (NVAX) Begins Phase 1/2 Clinical Trial of COVID-19 Vaccine
-
Novavax Initiates Phase 1/2 Clinical Trial of COVID-19 Vaccine
-
Novavax Initiates Phase 1/2 Clinical Trial of COVID-19 Vaccine
-
Novavax (NVAX) Announces $388M Funding from CEPI for COVID-19 Vaccine
-
Novavax Reports First Quarter 2020 Financial Results
-
Novavax Reports First Quarter 2020 Financial Results
-
Novavax to Receive up to $388 Million Funding from CEPI for COVID-19 Vaccine Development and Manufacturing
-
Novavax to Receive up to $388 Million Funding from CEPI for COVID-19 Vaccine Development and Manufacturing
-
Novavax (NVAX) to Present COVID-19 Vaccine Candidate Progress in World Vaccine Congress Webinar Series
-
Novavax to Present COVID-19 Vaccine Candidate Progress in World Vaccine Congress Webinar Series
-
Novavax to Present COVID-19 Vaccine Candidate Progress in World Vaccine Congress Webinar Series
-
Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 11, 2020
-
Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 11, 2020
-
Pre-Open Stock Movers 04/08: (GNMK) (NVAX) (APT) Higher; (TAL) (EHTH) (W) Lower (more...)
-
Novavax (NVAX) Reports Identification of Coronavirus Vaccine Candidate; Accelerates Initiation of First-in-Human Trial to Mid-May
-
Novavax Identifies Coronavirus Vaccine Candidate; Accelerates Initiation of First-in-Human Trial to Mid-May
-
Novavax Identifies Coronavirus Vaccine Candidate; Accelerates Initiation of First-in-Human Trial to Mid-May
-
Emergent BioSolutions (EBS) Enters Agreement with Novavax (NVAX) to Manufacture NanoFlu
-
Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™
-
Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™
-
Pre-Open Movers 03/24: (GSAT) (NVAX) (CTMX) Higher; (MIST) (BXRX) (HOTH) Lower (more...)
-
Novavax (NVAX) Reports NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial
-
Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial
-
Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial
-
Novavax Reports Fourth Quarter and Full Year 2019 Financial Results
-
Novavax Reports Fourth Quarter and Full Year 2019 Financial Results
-
Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate
-
Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate
-
Emergent BioSolutions (EBS) Reports Development & Manufacturing Agreement With Novavax (NVAX) for Experimental Vaccine Candidate for Coronavirus Disease
-
Novavax (NVAX) Secures $4M Funding from CEPI for COVID-19 Vaccine Development
-
Novavax Awarded Funding from CEPI for COVID-19 Vaccine Development
-
Emergent BioSolutions Signs Development and Manufacturing Agreement With Novavax for Experimental Vaccine Candidate for Coronavirus Disease
-
Novavax Awarded Funding from CEPI for COVID-19 Vaccine Development
-
Emergent BioSolutions Signs Development and Manufacturing Agreement With Novavax for Experimental Vaccine Candidate for Coronavirus Disease
-
Novavax to Host Conference Call to Discuss Fourth Quarter Financial Results on March 11, 2020
-
Novavax to Host Conference Call to Discuss Fourth Quarter Financial Results on March 11, 2020
-
Pre-Open Stock Movers 03/02: (FTSV) (TRIL) (TWTR) Higher; (BIOC) (ENLV) (NVAX) Lower (more...)
-
Novavax (NVAX) Advances Development of Novel COVID-19 Vaccine
-
Novavax Advances Development of Novel COVID-19 Vaccine
-
Novavax Advances Development of Novel COVID-19 Vaccine
-
Novavax (NVAX) Preclinical NanoFlu Data Published in Vaccines
-
Novavax’ Preclinical NanoFlu Data Published in Vaccines; Details Structural Basis for Broadly Neutralizing Immunity
-
Novavax’ Preclinical NanoFlu Data Published in Vaccines; Details Structural Basis for Broadly Neutralizing Immunity
-
Novavax (NVAX) Granted Fast Track Designation for NanoFlu in Older Adults
-
Novavax Granted Fast Track Designation for NanoFlu in Older Adults
-
Novavax Granted Fast Track Designation for NanoFlu in Older Adults
-
Novavax to Present at the 38th Annual J.P. Morgan Healthcare Conference
-
Novavax to Present at the 38th Annual J.P. Morgan Healthcare Conference

